Dr Contantine Tam is an expert in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma, and leads the Low Grade Lymphoma and CLL Stream at VCCC. He is a member of many Scientific Committees including the DVA Specialist Review Council, Hairy Cell Foundation, and the Australasian Leukemia and Lymphoma Group. Dr Tam is on the editorial board of Leukemia & Lymphoma, and has authored more than 100 research papers; his work has been cited over 2000 times in the literature. Dr Tam's clinical focus is the development of targeted drug combinations for treatment of CLL and NHL, with a long-term goal of achieving cure in these diseases.
2013 : Herman Fellowship in Translational Cancer Research, University of Melbourne
2010: Teaching Excellence Award, The University of Melbourne
2009: Sylvia and Charles Viertal Foundation Clinical Investigator Fellowship
2008: Merit Award, American Society of Clinical Oncology
2007: Merit Award, American Society of Clinical Oncology
2007: Travel Award, American Society of Hematology
2007: Janice Davis Singletary Fellowhship for Lymphoma Research, MD Anderson Cancer Center
2006: MD Anderson Cancer Center Fellowship in Patient-Oriented Research in CLL
2006: Young Investigator Award, Haematology Society of Australia and New Zealand
2005: Young Investigator Award, Haematology Society of Australia and New Zealand
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O’Dwyer M, Hellmann A, Suchuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ. Ibrutinib vs Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia. New England Journal of Medicine 2015, 373(25):2425-37.
McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib Increases the Risk of Atrial Fibrillation, Potentially Through Inhibition of Cardiac PI3K-Akt Signalling. Blood 2014, 124(25): 3829 – 3830. Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, Cole-Sinclair M, Reynolds J, Filshie R, Schischka S, Khot A, Sandhu S, Keating MJ, Nandurkar H, Tam CS. Ibrutinib Inhibits Collagen-Mediated But Not ADP-Mediated Platelet Aggregation. Leukemia 2015; 29(4):783-7.
Tam CS, O’Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ. Long-Term Results of First Salvage Treatment in CLL Patients Treated Initially with FCR (Fludarabine, Cyclophosphamide and Rituximab). Blood 2014; 124(20):3059-64.
Byrd J, Brown J, O’Brien S, Barrientos J, Kay N, Reddy N, Coutre S, Tam CS, Mulligan S, Jager U, Devereux S, Barr P, Furman R, Kipps T, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster S, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones J, Chu A, Fardia M, McGreivy J, Clow F, James D, Hillmen P. Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. New England Journal of Medicine 2014, 371 (3): 213–23.
Tam CS, Shanafelt TD, Wierda W, Abruzzo LV, Van Dyke DL, O’Brien S, Ferrajoli A, Lerner S, Lynn A, Kay NE, Keating MJ. De Novo Deletion 17p13.1 Chronic Lymphocytic Leukemia Shows Significant Clinical Heterogeneity: The MD Anderson and Mayo Clinic Experience. Blood 2009; 114:957-64.
Lin KI, Tam CS, Keating MJ, Wierda WG, O’Brien S, Lerner S, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. Relevance of the Immunoglobulin VH Somatic Mutation Status in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Related Chemoimmunotherapy Regimens. Blood 2009; 113: 3168-3171.
Tam CS, O’Brien S, Wierda W, Kantarjian H, Wen S, Do K, Thomas DA, Cortes J, Lerner S, Keating MJ. Long Term Results of the Fludarabine, Cyclophosphamide and Rituximab Regimen as Initial Therapy of Chronic Lymphocytic Leukemia. Blood 2008; 112: 975-980.